CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3
CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.